What is the official website of Dynavax Technologies ?

The official website of Dynavax Technologies is https://www.Dynavax.com.

What is Dynavax Technologies's cybersecurity risk score?

Dynavax Technologies has an AI-generated cybersecurity risk score of 742 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has Dynavax Technologies experienced?

According to Rankiteo, Dynavax Technologies currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Dynavax Technologies been affected by any supply chain cyber incidents ?

According to Rankiteo, Dynavax Technologies has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Dynavax Technologies have SOC 2 Type 1 certification ?

According to Rankiteo, Dynavax Technologies is not certified under SOC 2 Type 1.

Does Dynavax Technologies have SOC 2 Type 2 certification ?

According to Rankiteo, Dynavax Technologies does not hold a SOC 2 Type 2 certification.

Does Dynavax Technologies comply with GDPR ?

According to Rankiteo, Dynavax Technologies is not listed as GDPR compliant.

Does Dynavax Technologies have PCI DSS certification ?

According to Rankiteo, Dynavax Technologies does not currently maintain PCI DSS compliance.

Does Dynavax Technologies comply with HIPAA ?

According to Rankiteo, Dynavax Technologies is not compliant with HIPAA regulations.

Does Dynavax Technologies have ISO 27001 certification ?

According to Rankiteo,Dynavax Technologies is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Dynavax Technologies operate in ?

Dynavax Technologies operates primarily in the Biotechnology Research industry.

How many employees does Dynavax Technologies have ?

Dynavax Technologies employs approximately 327 people worldwide.

Does Dynavax Technologies own any subsidiaries ?

Dynavax Technologies presently has no subsidiaries across any sectors.

How many LinkedIn followers does Dynavax Technologies have ?

Dynavax Technologies's official LinkedIn profile has approximately 17,260 followers.

What is the NAICS classification code for Dynavax Technologies ?

Dynavax Technologies is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does Dynavax Technologies have a Crunchbase profile ?

No, Dynavax Technologies does not have a profile on Crunchbase.

Does Dynavax Technologies have a LinkedIn profile ?

Yes, Dynavax Technologies maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/dynavax-technologies.

How many cybersecurity incidents has Dynavax Technologies experienced ?

As of September 26, 2026, Rankiteo reports that Dynavax Technologies has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Dynavax Technologies have ?

Dynavax Technologies has an estimated 4,769 peer or competitor companies worldwide.

What types of cybersecurity incidents has Dynavax Technologies faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Dynavax Technologies

Boost Score +25 with badge (5 left)

742

/1000

Moderate

767

/1000

Fair

Dynavax Technologies Vendor Cyber Rating & Cyber Score

Dynavax.com

Add Your Compliance Badge

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn. Dynavax is an equal opportunity employer and prohibits

Dynavax Technologies

Dynavax Technologies CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Dynavax Technologie...

Breach

2/2020

DYN225072525

Loading…

A.I.

Dynavax Technologies Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Dynavax Technologies

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Dynavax Technologies in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Dynavax Technologies in 2026.

Incident Types Dynavax Technologies vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Dynavax Technologies in 2026.

Incident History - Dynavax Technologies (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Dynavax Technologies Subsidiaries

Dynavax Technologies

Biotechnology Research

Website: https://www.Dynavax.com

Company Size: 201-500 employees

Dynavax GmbHPharmaceutical Manufacturing

Loading…

Dynavax Technologies Similar Companies

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Fortrea

fortrea.com

Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

bioMérieux

biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

The National Institutes of Health

cb nih.gov

NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement

Syneos Health

cb syneoshealth.com

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

Loading…

NEWS

Dynavax Technologies CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

February 14, 2026 08:00 AM

Cybersecurity Stocks To Keep An Eye On – February 12th

Palo Alto Networks, CrowdStrike, Fortinet, Globant, and SentinelOne are the five Cybersecurity stocks to watch today, according to...

Read Article

February 10, 2026 08:00 AM

A Look At Dynavax Technologies (DVAX) Valuation As Pipeline Prospects Meet Conflicting Fair Value Estimates

Dynavax Technologies stock overview Dynavax Technologies (DVAX) has been drawing attention from investors primarily for its role as a...

Read Article

January 10, 2026 08:00 AM

Is It Time To Reassess Dynavax Technologies (DVAX) After Its Recent Share Price Surge

If you are asking whether Dynavax Technologies is reasonably priced at its current level, this article will walk through what the numbers...

Read Article

December 28, 2025 08:00 AM

Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)

Sanofi (NASDAQ:SNY) is one of the Best Affordable Stocks to Buy According to Analysts. On December 24, Sanofi (NASDAQ:SNY) announced...

Read Article

December 24, 2025 08:00 AM

Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal

Dec 24 (Reuters) - Sanofi (SASY.PA) , opens new tab said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.

Read Article

November 06, 2025 08:00 AM

Why Dynavax Technologies (DVAX) Is Up 5.7% After Launching a $100 Million Buyback and Raising Guidance

Dynavax Technologies announced in the past week that it will repurchase up to US$100 million of its common stock, reaffirmed its full-year...

Read Article

November 05, 2025 08:00 AM

Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +50.00% and -0.23%, respectively, for the quarter ended September...

Read Article

September 02, 2025 07:00 AM

Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Dynavax Technologies Corporation is placed fifth...

Read Article

July 06, 2025 07:00 AM

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-96795

SUMMARY

Horilla is an HR and CRM software. Prior to 2.0.0, HorillaListView.export_data in horilla_views/generic/cbv/views.py accepts an authenticated user's columns POST parameter, takes field_tuple[1], interpolates it into dynamic_fn_str as Python source, and passes the generated function definition to exec(). A crafted string that remains valid under ast.literal_eval can inject Python syntax into a default argument evaluated during function definition, allowing arbitrary operating-system commands to execute with the application process privileges, including root privileges in the shipped Docker image. This issue is fixed in version 2.0.0.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-86066

SUMMARY

Horilla is an HR and CRM software. Prior to 2.0.0, approve_validate_attendance_request at /attendance/approve-validate-attendance-request/ changes attendance_validated, is_validate_request_approved, approved_by, and related pending-request state through an HTTP GET before calling attendance.save(), so Django does not require CSRF validation for the action. An unauthenticated attacker can cause a logged-in manager with attendance.change_attendance to make a top-level request that carries the manager's SameSite=Lax session cookie, silently approving attendance with the victim's privileges and attributing the approval to the victim in the audit trail. This issue is fixed in version 2.0.0.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: )

cvss4

Base Score: 5.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:A/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-57449

SUMMARY

Actual is a local-first personal finance tool. Prior to 26.7.0, Actual Sync Server's CORS proxy is intended to let authenticated users fetch resources only from repositories listed in the official plugin allowlist. When `ACTUAL_GITHUB_TOKEN` is configured, the proxy automatically attaches the server's GitHub token to GitHub requests. The GitHub API allowlist check uses a raw `startsWith()` prefix test for `/repos/{owner}/{repo}` without requiring a path boundary after the repository name. If an allowlisted public plugin repository is `https://github.com/acme/plugin`, the proxy also accepts GitHub API URLs. Those URLs are outside the allowlisted repository but still pass because their API path starts with `/repos/acme/plugin`. The proxy then forwards the request with the server's `ACTUAL_GITHUB_TOKEN`, allowing any authenticated Actual user to read private GitHub resources reachable by that token. Version 26.7.0 fixes the issue.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: )

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/actualbudget/actual/security/advisories/GHSA-m62c-5q34-f3cf

CVE-2026-92842

SUMMARY

The convert.base64-encode, convert.quoted-printable-encode and convert.quoted-printable-decode stream filters accept a line-break-chars option whose length is tracked separately from the string itself. The filter constructors duplicate the value with pestrdup(), which stops at the first NUL byte, while keeping the original length. When the filter later emits a line break it copies the recorded length out of the truncated allocation, reading past its end and placing adjacent heap bytes into the filter output.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

https://github.com/php/php-src/security/advisories/GHSA-88hq-2827-7pg6

CVE-2026-91768

SUMMARY

The IPv6 branch of the FastCGI client access check compares only the first 12 bytes of a 16-byte IPv6 address, so listen.allowed_clients matches on a /96 prefix instead of the exact address. An attacker who can source an address sharing the first 96 bits with an allowed one passes the check and reaches the FastCGI endpoint.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://github.com/php/php-src/security/advisories/GHSA-62xp-839h-2637

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Dynavax Technologies Vendor Cyber Rating & Cyber Score

Dynavax Technologies A.I CyberSecurity Scoring

Dynavax Technologies CyberSecurity News & History

Dynavax Technologies Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Dynavax Technologies

Incidents vs Biotechnology Research Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Dynavax Technologies vs Biotechnology Research Industry Avg (This Year)

Incident History - Dynavax Technologies (X = Date, Y = Severity)

Dynavax Technologies Subsidiaries

Dynavax Technologies

Dynavax Technologies Similar Companies

Agilent Technologies

Fortrea

Charles River Laboratories

ICON plc

bioMérieux

Roche

CSL

The National Institutes of Health

Syneos Health

Dynavax Technologies CyberSecurity News

Cybersecurity Stocks To Keep An Eye On – February 12th

A Look At Dynavax Technologies (DVAX) Valuation As Pipeline Prospects Meet Conflicting Fair Value Estimates

Is It Time To Reassess Dynavax Technologies (DVAX) After Its Recent Share Price Surge

Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)

Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal

Why Dynavax Technologies (DVAX) Is Up 5.7% After Launching a $100 Million Buyback and Raising Guidance

Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates

Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Dynavax Technologies CyberSecurity News & History

Dynavax Technologies Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Dynavax Technologies

Incidents vs Biotechnology Research Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Dynavax Technologies vs Biotechnology Research Industry Avg (This Year)

Incident History - Dynavax Technologies (X = Date, Y = Severity)

Dynavax Technologies Subsidiaries

Dynavax Technologies

Dynavax Technologies Similar Companies

Agilent Technologies

Fortrea

Charles River Laboratories

ICON plc

bioMérieux

Roche

CSL

The National Institutes of Health

Syneos Health

Dynavax Technologies CyberSecurity News

Cybersecurity Stocks To Keep An Eye On – February 12th

A Look At Dynavax Technologies (DVAX) Valuation As Pipeline Prospects Meet Conflicting Fair Value Estimates

Is It Time To Reassess Dynavax Technologies (DVAX) After Its Recent Share Price Surge

Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)

Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal

Why Dynavax Technologies (DVAX) Is Up 5.7% After Launching a $100 Million Buyback and Raising Guidance

Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates

Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo